FDA (FDA) News
Follow FDA (FDA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
REGULATION | Jul 06, 2026, 01:01 PM UTC
L
Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engag
FORT LAUDERDALE, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE A
REGULATION | Jul 06, 2026, 12:31 PM UTC
L
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Highlights Expanding Commercial Adoption of Pro
REGULATION | Jul 06, 2026, 12:12 PM UTC
L
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with
REGULATION | Jul 06, 2026, 12:01 PM UTC
L
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: GDAI
REGULATION | Jul 06, 2026, 12:00 PM UTC
L
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to tre
REGULATION | Jul 06, 2026, 10:50 AM UTC
L
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor
Ascletis Submits Two IND Applications to the U.S. FDA f
REGULATION | Jul 06, 2026, 01:11 AM UTC
M
FDA: Names 3 Finalists
Three finalists emerge to lead the FDA
REGULATION | Jun 26, 2026, 02:50 PM UTC
L
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGULATION | Jun 22, 2026, 11:00 AM UTC